Market Overview

Morgan Stanley Reiterates Overweight Rating on Watson Pharmaceuticals

Related WPI
Watson Pharma Buys Uteron Pharma SA
UPDATE: Goldman Sachs Downgrades Watson Pharmaceuticals to Neutral on Limited Upside

In a report published Monday, Morgan Stanley reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI).

Morgan Stanley noted, “We did not know that Covidien was pursuing generic Concerta (we were not aware of any Paragraph IV litigation), nor that it would qualify for exclusivity on the 27, 36, and 54 mg doses (85% of total franchise IMS sales). The 27 mg dose (15% of sales) launches immediately, and Covidien plans to launch the 36 and 54 mg doses (70% of sales) in 1Q:13. According to Covidien's press release, exclusivity is triggered upon commercial launch of each respective dose.”

Watson Pharmaceuticals closed on Friday at $89.04.

Latest Ratings for WPI

DateFirmActionFromTo
Jan 2013Goldman SachsDowngradesBuyNeutral
Nov 2012Piper JaffrayUpgradesNeutralOverweight
Nov 2012Credit SuisseMaintainsOutperform

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (WPI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional